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http://dx.doi.org/10.1016/j.ccell.2015.05.009SUMMARYResistance to chemotherapy represents a major obstacle for long-term remission, and effective strategies
to overcome drug resistance would have significant clinical impact. We report that recurrent ovarian carci-
nomas after paclitaxel/carboplatin treatment have higher levels of spleen tyrosine kinase (SYK) and phos-
pho-SYK. In vitro, paclitaxel-resistant cells expressed higher SYK, and the ratio of phospho-SYK/SYK
positively associated with paclitaxel resistance in ovarian cancer cells. Inactivation of SYK by inhibitors or
gene knockdown sensitized paclitaxel cytotoxicity in vitro and in vivo. Analysis of the phosphotyrosine pro-
teome in paclitaxel-resistant tumor cells revealed that SYK phosphorylates tubulins and microtubule-asso-
ciated proteins. Inhibition of SYK enhanced microtubule stability in paclitaxel-resistant tumor cells that were
otherwise insensitive. Thus, targeting SYK pathway is a promising strategy to enhance paclitaxel response.INTRODUCTION
Development of resistance to chemotherapeutic agents is a
prevalent and challenging problem inmanaging cancer (Holohan
et al., 2013). The high morbidity and mortality associated with
many types of human cancer are attributed to the emergence
of tumor cells that are refractory to cytotoxic chemotherapy
and clonally develop into recurrent tumors. Although The Cancer
Genome Atlas and several other genome-wide studies have re-Significance
There is an unmet need to introduce more effective drugs to
agents. Here, we demonstrated that inactivating spleen tyrosi
cells to the cytotoxic effects of paclitaxel, overcoming pac
microtubules through dephosphorylation of microtubule andm
from paclitaxel. As a result, SYK inhibitor and paclitaxel forme
those that were paclitaxel-resistant. Our results provide critic
in combination with paclitaxel in cancer patients, and warrant
combined therapy.
82 Cancer Cell 28, 82–96, July 13, 2015 ª2015 Elsevier Inc.vealed the molecular landscapes of cancer, these studies mainly
focus on primary tumors (Vogelstein et al., 2013). It is critical,
however, to study recurrent tumors and elucidate the molecular
etiology of drug resistance. Toward this goal, we previously
studied ovarian high-grade serous carcinoma (HGSC) to identify
genes and the pathways they controlled in the development of
recurrent disease. HGSC is the most common and lethal type
of ovarian cancer (Cho and Shih, 2009); most patients are
diagnosed with advanced-stage disease and require first-lineenhance therapeutic effects of current chemotherapeutic
ne kinase (SYK) using small compound inhibitors sensitized
litaxel resistance. We found that SYK inhibitors stabilized
icrotubule-associated proteins, a mechanism that is distinct
d a synergistic cytotoxic effect in tumor cells, especially in
al pre-clinical evidence proposing the use of SYK inhibitors
future clinical studies to assess the clinical benefit of such
therapy, which involves cytoreductive surgery followed by com-
bined carboplatin and paclitaxel chemotherapy. Although HGSC
generally responds to this standard chemotherapy at the begin-
ning of its course, relapse usually occurs and requires further
therapy including the weekly paclitaxel regimen. Unfortunately,
only a small percentage (10%–15%) of patients with advanced
disease achieve long-term remission.
In a previous study, we compared proteomes between pri-
mary and recurrent post-chemotherapy HGSC tissues from the
same patients (Jinawath et al., 2010). Among the preferentially
expressed proteins identified in recurrent HGSCs, the non-re-
ceptor tyrosine kinase, spleen tyrosine kinase (SYK), was of in-
terest because more than half of the recurrent tumors expressed
higher levels of SYK than did the primary tumors (Jinawath et al.,
2010). This is significant because small molecule inhibitors that
target SYK, such as fostamatinib (R788), are available for pre-
clinical testing and for future clinical trials in patients with ovarian
cancer (Ruzza et al., 2009).
Originally isolated from bovine thymus (Zioncheck et al., 1986)
and later identified in activated B lymphocytes (Hutchcroft et al.,
1991; Zioncheck et al., 1988), SYK regulates adaptive immune
receptor signaling, cell proliferation, differentiation, and survival.
SYK has been reported as a candidate oncogene in B cell leuke-
mia and lymphomas, gastric carcinoma, and head and neck can-
cer (Buchner et al., 2009; Feldman et al., 2008; Luangdilok et al.,
2007; Mo´csai et al., 2010; Nakashima et al., 2006). SYK expres-
sion has an anti-apoptotic effect on B-lymphoma cell lines
through phosphorylation of nucleolin, which stabilizes the
mRNA of anti-apoptotic Bcl-x(L) (Wang et al., 2014). Paradoxi-
cally, SYK expression may block tumor progression in breast
cancer because loss of its expression is associated with poor
prognosis and tumor metastasis (Coopman et al., 2000). The ev-
idence thus suggests that SYK can either negatively or positively
regulate tumor progression, depending on the biological context
and tissue lineage (Geahlen, 2014).
The purpose of this study is to determine how SYK contributes
to chemoresistance in ovarian cancers and to establish a biolog-
ical foundation for introducing SYK inhibitors to potentiate the
anti-tumor effects of chemotherapeutic drugs. We also seek to
identify candidate SYK substrates involved in drug resistance,
and the results should have translational implications to improve
chemotherapy and clinical outcomes in patients with cancer.
RESULTS
Recurrent Ovarian Tumors Express Higher Levels of
SYK and Phosphorylated SYK
To compare the expression levels of SYK in paired recurrent
post-chemotherapy ovarian HGSC and their primary untreated
tumors, we performed immunohistochemistry using two anti-
bodies, one specific for SYK and the other specific for its active
(autophosphorylated) form, p-SYK (Y525/526). Using theH score
to semi-quantify immunoreactivity, we found that H scores for
SYK were higher in the recurrent ovarian HGSC specimens
than in the primary counterparts (Figure 1A), and H scores for
active p-SYK (Y525/526) were higher in recurrent tumors than
in primary tumors (Figure 1B). Likewise, H scores of total SYK
or p-SYK positively correlated to each other (Figure 1C). Repre-
sentative staining for p-SYK in a pair of matched primary andrecurrent ovarian HGSC is shown in Figure 1D. Aside from
HGSC, upregulated SYK expression was also observed in four
of six cases of recurrent post-chemotherapy ovarian clear cell
carcinomas as compared to matched primary tumors (Fig-
ure S1A). We further examined SYK expression using immuno-
histochemistry in 214 serous ovarian carcinoma effusions (Table
S1; see the Supplemental Experimental Procedures for the
cohort information) and observed an association (p = 0.005)
between higher SYK staining intensity and less favorable chemo-
response to paclitaxel/platinum-based combination therapy.
These data support that SYK upregulation is associated with
chemoresistance.
Association between Paclitaxel Resistance and SYK
Because the recurrent HGSC tissues were obtained from
patients who were previously treated with carboplatin and
paclitaxel combination therapy, we sought to determine if SYK
overexpression was related to resistance of carboplatin or pacli-
taxel. We analyzed two ovarian cancer cell lines, SKOV3 and
MPSC1, from which carboplatin resistant and paclitaxel-resis-
tant (TR) clones were previously established (Jinawath et al.,
2009, 2010). We found that paclitaxel-resistant SKOV3TR and
MPSC1TR expressed higher levels of SYK and p-SYK (Y525/
526) than the parental cells (Figures 1E and 1F), suggesting
that SYK upregulation was related to biological resistance to
paclitaxel and is unlikely due to acute induction by paclitaxel in
naive cells (Figure S1B).
To examine if there is an association between SYK activity and
response to paclitaxel, we analyzed a panel of 25 primary ovarian
cancer cell cultures and cell lines expressing different levels of
SYK by immunoblotting (Figure S1C). The degree of paclitaxel
sensitivity in these cells was determined by their half-maximal
inhibitory concentration (IC50) values. A significant positive cor-
relation was observed between p-SYK/SYK ratios and the IC50
of paclitaxel but not carboplatin (Figure 1G), suggesting that
active SYK is an important determinant of paclitaxel resistance.
Inactivation of SYK Suppresses Cell Growth in Ovarian
Cancer Cells
To determine if SYK can be a therapeutic target in ovarian
cancer, we inactivated SYK using shRNAs or small molecule
inhibitors. We found that SYK knockdown, as compared to
control knockdown, significantly reduced cell numbers in naive
(parental) SKOV3 and MPSC1 as well as in their corresponding
paclitaxel-resistant clones, although the SYK knockdown
achieved in resistant cells was not as pronounced as in the naive
cells (Figure 2A). Next, we treated SKOV3 cells with the SYK in-
hibitor R406 (the activemetabolite of fostamatinib) and observed
that R406 suppressed SYK autophosphorylation at Y525/526
and Y352, which was considered an indicator for SYK activation
(Figure 2B) and resulted in concentration-dependent inhibition of
SYK activity asmeasured by reduction of p-SYK (Y525/526) (Fig-
ure S2A). We further observed that R406 inhibited proliferation
in a dose-dependent manner in SKOV3, SKOV3TR, MPSC1,
and MPSC1TR cells (Figure 2C).
Next, we determined the sensitivity to R406 in a panel of cell
lines with various levels of endogenous SYK expression (Fig-
ure 2D). Based on western blot analysis, we separated cell lines
into SYK-expressing and undetectable groups and observedCancer Cell 28, 82–96, July 13, 2015 ª2015 Elsevier Inc. 83
0 1 2 3
0
1
2
3
4
r= 0.691, p<0.0001
total SYK
p-
SY
K
Primary Recurrent
0.0
0.5
1.0
1.5
2.0
2.5
3.0
H-
sc
or
e 
of
 S
YK
 s
ta
in
in
g
p= 0.0048
Primary Recurrent
0.0
0.5
1.0
1.5
2.0
2.5
3.0
H-
sc
or
e 
of
 p
-S
YK
 s
ta
in
in
g
(Y
52
5/
52
6)
p= 0.017
primary     recurrent 
naive TR naive TR
0
1
2
3
4
5
MPSC1SKOV3
m
RN
A 
fo
ld
 c
ha
ng
e
(n
or
m
al
iz
ed
 to
 A
PP
)
SYK
GAPDH
naive  TR naive   TR
MPSC1SKOV3 
p-SYK
(Y525/526)
D E F
A B C
G
0 10 20
0
2
4
6
8
2000 4000 6000 8000
r= 0.5
p= 0.01
Paclitaxel IC50 (nM)
p-
SY
K 
(Y
52
5/
52
6)
/S
YK
 ra
tio
0 100 200 300 400
0
2
4
6
8
r= 0.2
p= 0.4
Carboplatin IC50 (μM)
p-
SY
K 
(Y
52
5/
52
6)
/S
YK
 ra
tio
Figure 1. Expression of SYK and Phosphor-
ylated SYK in Primary and Recurrent
Ovarian Cancers
(A and B) Immunohistochemistry shows levels
of SYK (A) and phospho-SYK (p-SYK, Y525/526)
(B) in recurrent ovarian HGSCs compared to pri-
mary untreated specimens from the same patients
based on paired two-tailed t test (n = 23 pairs).
H score is used to semi-quantify the expression
levels. The bottom and top of the boxplots repre-
sent the first and third quartiles, the band inside the
box is the median, and the lines above and below
the box indicate the maximum and minimum of all
of the data.
(C) Correlation of H scores between total SYK and
p-SYK levels.
(D) Representative images of p-SYK staining from
matched primary and recurrent tumors. Scale bars
represent approximately 400 mm (top) and 40 mm
(bottom).
(E and F) mRNA (E) and protein (F) expression of
SYK and p-SYK in SKOV3 and MPSC1 naive and
paclitaxel-resistant (TR) cells.
(G) Pearson correlation analysis between p-SYK/
SYK ratio and paclitaxel or carboplatin sensitivity
(as determined by IC50) in a panel of primary
ovarian cancer cell cultures (red) and cell lines
(black). Results are shown as ± SEM. See also
Figure S1 and Table S1.significantly greater sensitivity to R406 (lower IC50 values) in
SYK-expressing cell lines than in cell lines with undetectable
levels of SYK expression (Figure 2E). Calculation of Spearman’s
rank correlation coefficient demonstrated a negative correlation
between SYK expression and the IC50 values for R406 (Fig-
ure 2F). Similarly, an inverse correlation between p-SYK (Y525/
526) expression levels and the IC50 values of R406 was observed
in these cell lines (Figure S2B).
SYK Inhibitors Enhance Paclitaxel Sensitivity
We then tested the effect of combining R406 with chemo-
therapeutic agents including paclitaxel, docetaxel, carboplatin,
5-fluorouracil, doxorubicin, mitomycin C, and methotrexate.
Based on the drug combination index, we found that microtu-
bule-targeting agents, including paclitaxel and docetaxel, had
a synergistic effect with R406, whereas other drugs, including
carboplatin, produced no such effect (Figures 3A and S3A).
The ability of SYK inhibitor to enhance paclitaxel cytotoxicity
was dose dependent because higher R406 concentrations
were associated with a greater inhibitory effect (Figure 3B).
Enhancement of paclitaxel sensitivity was also observed by
SYK knockdown using shRNAs (Figures S3B and S3C) and
siRNAs (Figures S3D and S3E). In other primary ovarian tumor
cell cultures and ovarian cancer cell lines that exhibited high
intrinsic resistance to paclitaxel (IC50R 5 nM), the combination84 Cancer Cell 28, 82–96, July 13, 2015 ª2015 Elsevier Inc.of paclitaxel and SYK inhibitors was also
synergistic (Figure 3D; Figure S3F). The
use of other SYK inhibitors including
P505-15/PRT062607 and GS-9973 (Fig-
ure 3C) (Currie et al., 2014; Hoellenriegel
et al., 2012) produced a similar result. Incell lines with high levels of SYK, including OVCAR3 and
OVCA429, the same synergistic effect was also observed (Fig-
ure S3F). These data suggest that the effect observed from
R406 was unlikely due to non-specific pan-kinase inhibition.
The effect of R406 on paclitaxel-induced cytotoxicity was
further compared between paclitaxel-resistant and -naive cells.
We found that treatment with SYK inhibitors resulted in a
prominent shift of the paclitaxel IC50s in both SKOV3TR and
MPSC1TR cells compared to parental SKOV3 and MPSC1 cells.
Specifically, the ratio of paclitaxel IC50 in untreated to R406
treated SKOV3 cells was 2.5, whereas in SKOV3TR it was 236
(Figure 3E). The ratio of paclitaxel IC50 for MPSC1 cells in un-
treated cells to R406 treated cells was 8, whereas in MPSC1TR
it was 12,429 (Figure 3F), suggesting that paclitaxel-resistant
cells were much more sensitive to the combined SYK inhibitor
and paclitaxel treatment than their parental counterparts. The
other SYK inhibitors also showed synergistic relationship with
paclitaxel in the resistant SKOV3TR and MPSC1TR cells
(Figure S3F).
Combination of R406 and Paclitaxel Induces G2/M
Arrest and Enhances Apoptosis
Because paclitaxel targets microtubules, the above results
suggested that SYK may also regulate microtubule function,
which is essential for mitosis. Therefore, we quantified cell cycle
AB
D
E F
C
Figure 2. SYK Knockdown or SYK Inhibitor Reduces Ovarian Cancer Cell Growth
(A) Immunoblot shows SYK knockdown efficiency 48 hr after transduction with lentivirus expressing SYK shRNAs as compared to control shRNA (pLKO.1).
GAPDH is the loading control. Cell numbers are determined daily. **p < 0.01; ***p < 0.001 as determined by two-way ANOVA with Bonferroni posttests.
(B) Western blot analysis of SKOV3 tumor spheroids 48 hr after R406 (2.5 mM) treatment.
(C) The effect of R406 on cellular proliferation.
(D) Immunoblot shows SYK expression levels in indicated cell lines.
(E) R406 IC50 in cells with or without detectable SYK expression (paired t test). The bottom and top of the boxplots represent the first and third quartiles, the band
inside the box is the median, and the lines above and below the box indicate the maximum and minimum of all of the data.
(F) Spearman correlation analysis between SYK expression levels and R406 IC50 values. Results are shown as ± SEM. See also Figure S2.
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Figure 3. Combination of SYK Inhibitor and Paclitaxel Produces a Synergistic Cytotoxicity
(A) Logarithmic combination index plot of R406 (2.5 mM) is generated in combination with paclitaxel, docetaxel or carboplatin in paclitaxel-resistant
SKOV3TR cells.
(B) Cell viability assay in SKOV3TR cells treated with paclitaxel and R406 at indicated concentrations.
(C) Structures of SYK inhibitors used in the study.
(D) Heatmaps of cell viability after treatment with paclitaxel or combination of SYK inhibitor and paclitaxel in primary ovarian cancer cells and cell lines. PT,
paclitaxel; R, R406; P, P505-15/PRT062607; G, GS-9973. Blue to red: cell viability from low to high.
(E and F) Dose-response curves showing the effect of addition of R406 to paclitaxel in paclitaxel-resistant cells as compared to naive SKOV3 cells (E) or MPSC1
cells (F). Results are shown as ± SEM. See also Figure S3.
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distribution in cells treated with R406, paclitaxel, or their combi-
nation. It is known that paclitaxel induces microtubule stabiliza-
tion and leads to mitotic block in the late G2/M phase of the cell
cycle. Based on high-throughput imaging analysis of in vitro cell
cultures using Hoechst 33342 staining of DNA, we were able to
confirm that paclitaxel increased the fraction of SKOV3 cells at
the G2/M phase 8 hr, 12 hr, or 16 hr after treatment (Figures
S3G and S3H). In contrast, SKOV3TR cells did not respond to
paclitaxel treatment alone, but arrested in G2/M phase only
when the cells were co-treated with R406. In addition, the levels
of apoptosis markers, cleaved PARP, and caspase 7 (Figure S3I)
and annexin V staining (Figure S3J) increased when cells were
co-treated with R406 and paclitaxel compared to the cells
treated with vehicle control, R406, or paclitaxel only.
Combination of R406 and Paclitaxel Inhibits Tumor
Growth in Naive and Paclitaxel-Resistant Ovarian Tumor
Xenograft
Two mouse models were used to assess the anti-tumor effect
of R406, paclitaxel, and the combination. In the first model,
SKOV3c.2 cell line was used because this subclone of SKOV3
was tumorigenic subcutaneously and expressed a relatively
higher level of SYK (Figure 2D). Athymic mice bearing the
SKOV3c.2 subcutaneous tumors were treated with paclitaxel
(8 mg/kg), R406 (6.5 mg/kg), or the combination. Drugs were
administered over several 3 days on/3 days off cycles initiated
when the tumors first becamepalpable (FigureS4A).We intended
to use a low dose of paclitaxel and R406 to determine the combi-
national anti-tumor effect and minimize adverse effects. At the
given doses, there was no significant difference in tumor weight
between the control group and the groups treated with either
single R406 or paclitaxel after four cycles of treatment (Figures
4A–4C). However, a significant reduction in tumor weight was
recorded in the group co-treated with R406 and paclitaxel
compared to the control group (p < 0.0004). The percentage of
tumor cells that incorporated bromodeoxyuridine (BrdU) was
significantly lower in tumors receiving the combined R406 and
paclitaxel than in other groups (p = 0.01) (Figure 4B). R406-
treated tumors in mice showed a reduction of the p-SYK (Y525/
526)/SYK ratio (Figure S4B). No significant differences were
detected between groups treated with R406 alone and paclitaxel
alone. Body weight, physical activity, and splenic weight of mice
in these groups were similar (Figures S4C and S4D).
Next, we determined if the paclitaxel and R406 combination
was effective in suppressing intraperitoneal tumor growth in
an in vivo paclitaxel-resistant ovarian cancer model. We estab-
lished intraperitoneal SKOV3Luc tumors in mice that recurred
after continuous paclitaxel treatment for 7 weeks (Figure 4D).
Compared to tumors grown in mice treated with vehicle, tumors
that recurred inmice treated with paclitaxel showed higher levels
of p-SYK (Y525/526) and SYK (Figure S4E). In primary cultures,
cells from recurrent paclitaxel-treated tumors were more resis-
tant to paclitaxel than cells from vehicle-treated tumors (Fig-
ure 4D). The cells from the paclitaxel-resistant tumor (pacli-
taxel-1) were then re-injected intraperitoneally in a new cohort
of mice followed by treatment with either vehicle, R406, pacli-
taxel or the combination. The new xenografts responded to
paclitaxel initially, but regrew after week 3. Paclitaxel and R406
combination significantly reduced tumor progression in thismodel as compared to paclitaxel alone at week 4 and 5. R406
alone at the applied dose did not show any anti-tumor effect
as compared to vehicle control (Figures 4E and 4F). Similar to
a previous report (Braselmann et al., 2006), we did not detect
gross or microscopic abnormalities in organs from these R406-
treated mice. The above results indicate that the combination
of paclitaxel and R406 effectively inhibited tumor growth at
doses that were highly tolerable in mice.
Identification of Substrates Phosphorylated by SYK in
Paclitaxel-Resistant Tumor Cells
To elucidate the molecular mechanisms by which SYK inhibition
enhanced cytotoxic effects of paclitaxel, we performed stable
isotope labeling by amino acids in cell culture (SILAC) (Ong
et al., 2002) and compared the phosphoproteome between
SKOV3TR cells treated with R406 and vehicle control. Based
on two independent experiments, we identified 896 unique,
differentially expressed phosphopeptides corresponding to
516 proteins (Table S2), more than 90% of which belonged to
phosphotyrosine-containing peptides. Because we were inter-
ested in those proteins that were potentially phosphorylated
by SYK, we focused on the phosphorylation sites that were
downregulated (average H/L ratio <0.7) by R406 in duplicate
experiments. As a result, there were 327 downregulated phos-
phopeptides belonging to 228 proteins. Among them, 141 pep-
tides contained at least one acidic residue surrounding the
phosphorylated Tyr, and were, therefore, considered potential
substrates for SYK (Xue et al., 2012, 2013). Several SYK sub-
strates identified in this study, including SYK itself and PLCG1,
LCK, STAT3, and a-tubulin, have been previously reported to
be SYK substrates in hematopoietic cells (Couture et al., 1996;
Law et al., 1996; Peters et al., 1996; Uckun et al., 2010b). This
finding indicated the robustness of our approach in identifying
SYK substrates in ovarian cancer cells.
Pathway analysis indicated that the identified SYK substrates
participate in cell motility and organization of cytoskeleton in
addition to proliferation/growth, cell death, and survival among
other processes (Figures 5A–5C). Specifically, we identified
19 phosphosites (Table 1) in the following proteins: dynactin 2
(DCTN2), microtubule-associated protein 1B (MAP1B), microtu-
bule-associated protein 4 (MAP4), tubulin binding co-factor B
(TBCB), a-tubulin, and b-tubulin, all of which are proteins essen-
tial for microtubule dynamics. Table S3 lists phosphopeptides
we identified that were also reported in B lymphocytes and
breast cancer cells in a recent study that used an independent
method (Xue et al., 2012).
We selected representative SYK substrates including
a-tubulin, b-tubulin, MAP4, and MAP1B for further validation
because these proteins are constituents of the microtubules,
and their posttranslational modification such as phosphorylation
may have a direct impact on microtubule stability. Consistent
with a previous report (Faruki et al., 2000), we were able to
demonstrate phosphorylation of tubulin by SYK. Importantly,
our data from an in vitro kinase assay using active recombinant
SYK and purified bovine microtubule-associated protein
(MAPs) demonstrated that MAP1B and MAP4 were substrates
of SYK (Figure 5D). Furthermore, co-immunoprecipitation assays
demonstrated that SYK inhibitors (R406 and GS-9973) reduced
the levels of Tyr-phosphorylated a- and b-tubulin, although theCancer Cell 28, 82–96, July 13, 2015 ª2015 Elsevier Inc. 87
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Figure 4. Combination of Paclitaxel and R406 Decreases Tumor Growth in Mice
(A–C) Tumor weights (A), BrdU incorporation into tumors (B), and representative tumor-bearing mice (C) of the SKOV3c.2 subcutaneous tumor model treated as
indicated. Tumor weights are plotted and analyzed by one-way ANOVA followed by Tukey’s post hoc test.
(D) The growth of intraperitoneal SKOV3Luc tumors in vehicle-treated (vehicles 1 and 2) and in paclitaxel-treated (paclitaxel 1 and 2) mice. Paclitaxel IC50 values of
the tumors from the four mice were determined in individual primary cultures.
(E) Mice injected intraperitoneally with cells isolated from the paclitaxel-1 tumor were treated as indicated and the luminescence signals were analyzed by
two-way ANOVA with Bonferroni posttests.
(F) The luminescence of the intraperitoneal SKOV3Luc tumor xenografts from different treatment groups at the indicated week. **p < 0.01; ***p < 0.001. Results are
shown as ± SEM. See also Figure S4.effect of P505-15 was modest. The induction of MAP4 and
MAP1B Tyr phosphorylation by the Tyr phosphatase inhibitor
pervanadate, which is known to activate SYK signaling (Faruki
et al., 2000), was suppressed by SYK inhibitors (Figure S5A).
SYK knockdown by siRNA demonstrated a similar result (Fig-
ure S5B). Collectively, these data show that tubulin and MAPs
are direct SYK substrates.88 Cancer Cell 28, 82–96, July 13, 2015 ª2015 Elsevier Inc.Next, we compared the expression of total and Tyr-phos-
phorylated a- and b-tubulin, MAP4, and MAP1B between pacli-
taxel-sensitive (SKOV3 and MPSC1) and paclitaxel-resistant
cells (SKOV3TR and MPSC1TR) cells. Consistent with an
elevated SYK level in paclitaxel-resistant cells, Tyr-phosphory-
lated a-tubulin (Figure 5E), but not Tyr-phosphorylated b-tubulin,
was upregulated in these resistant cells (Figure S5C). Similarly,
total MAP1B and its Tyr-phosphorylated form were also upre-
gulated in the paclitaxel-resistant cells (Figure 5E). In a panel of
ovarian cancer cell lines, higher expression levels of ptyr-
MAP1B/MAP1B were associated with less sensitivity to pacli-
taxel (Figures 5F and S5D), further suggesting the involvement
of MAP1B tyrosine phosphorylation in paclitaxel resistance.
Using immunohistochemistry with the antibody against phos-
pho-a-tubulin (Y272) in 161 HGSC samples, we observed a
positive correlation in staining intensity between total SYK and
phospho-tubulin, and between phospho-SYK and phospho-
atubulin (Figure 5G). Two representative cases with high and
low staining intensity of SYK, phospho-SYK, and phospho-
a-tubulin are shown in Figure 5H.
Expression of Active SYK Confers Paclitaxel Resistance
and Increases MAP1B and MAP4 Tyrosine
Phosphorylation
To demonstrate whether activating the SYK pathway is sufficient
to confer paclitaxel resistance, we generated tetracycline-induc-
ible SKOV3 cells to ectopically express wild-type or active SYK
mutant (SYK-130E), which has been shown to have a high basal
kinase activity (Keshvara et al., 1997). Paclitaxel IC50 significantly
increased in ovarian cancer cells after induction of SYK-130E,
and to a lesser extent of SYK (Figures 6A and 6B), indicating
that SYK activation is sufficient to render paclitaxel resistance.
Moreover, cells expressing constitutively active SYK-130E
demonstrated increased Tyr-phosphorylated MAP1B and
MAP4, but not tubulin (Figure 6C). Using an in vitro microtubule
binding assay, we observed that SYK phosphorylated MAP1B
and MAP4 could still bind microtubule (Figure S6, comparing
SYK 0.4 mg sample plus/minus ATP), but the presence of R406
further increased their binding.
SYK Inhibition Stabilizes Microtubules in Paclitaxel-
Resistant Tumor Cells Co-treated with Paclitaxel
Two different approacheswere used to determinewhether inhib-
iting SYK activity would stabilize microtubules. First, we as-
sessed twomarkers ofmicrotubule stability, acetylated a-tubulin
(L’Hernault and Rosenbaum, 1985; Piperno and Fuller, 1985) and
detyrosinated (Glu) a-tubulin (Gundersen et al., 1984; Thomp-
son, 1977). Western blot analysis demonstrated that paclitaxel
markedly increased both acetylated and detyrosinated tubulin
levels in paclitaxel-sensitive SKOV3 and MPSC1 cells, but the
effect was only modest in paclitaxel-resistant SKOV3TR and
MPSC1TR cells (Figure 7A), indicating that the paclitaxel-resis-
tant cells had developed a mechanism(s), presumably by
increasing phosphorylation of tubulin and MAPs (Figure 5E), to
counteract paclitaxel-induced microtubule stability. Neither
acetylated nor detyrosinated tubulin levels were altered by
R406 alone at the applied concentration (2.5 mM) in either pacli-
taxel-resistant cell line, although R406 at a higher concentration
increased the levels of acetylated a-tubulin in paclitaxel-
sensitive and -resistant SKOV3 cells (Figure S7A). Compared
to vehicle control, R406 alone, and paclitaxel alone, R406 and
paclitaxel combination significantly increases the level of
acetyl-a-tubulin in SKOV3TR and MPSCTR cells. This finding
was not observed in naive cells because they are highly sensitive
to paclitaxel in stabilizing microtubules at the given paclitaxel
concentration (Figure 7A). Combination with other SYK inhibitorsshowed similar results (Figure S7B). The above findings were
confirmed by immunofluorescence (Figure S7C). Ovarian cancer
cell lines, KK, KOC7C, and OVTOKO, all of which were more
resistant to paclitaxel than the naive SKOV3 and MPSC1 cells
showed similar enhancement of acetylated a-tubulin in the com-
bination treatment (Figure 7A). To further extrapolate the finding
to an in vivo setting, we compared levels of acetyl-a-tubulin in
SKOV3c.2 tumor xenografts in mice treated with paclitaxel,
R406, or their combination. We observed a significant increase
in the acetylated-a-tubulin level in tumor xenografts treated
with combined R406 and paclitaxel (Figure 7B). The results of
these experiments suggested that inhibition of SYK in the pres-
ence of paclitaxel augmentedmicrotubule stabilization and cyto-
toxicity in paclitaxel-resistant tumor cells that were otherwise
insensitive to paclitaxel.
In the second approach, we applied live-cell microscopy to re-
cord microtubule dynamics in SKOV3 and SKOV3TR cells stably
transfected with GFP-a-tubulin. We used the fluorescence re-
covery after photobleaching (FRAP) technique to measure the
speed of microtubule turnover in these cells. We observed that
cells treated with R406 alone (2.5 mM) did not show any detect-
able changes in fluorescence recovery in SKOV3 cells. As ex-
pected, SKOV3 cells responded to paclitaxel treatment with a
reduced mobile fraction and an increased half-life after photo-
bleaching (Figure 7C). In contrast, SKOV3TR cells were less
responsive to paclitaxel, but adding R406 (2.5 mM) to paclitaxel
(30 nM) significantly reduced fluorescence recovery, including
a decreased mobile fraction and an increased half-life (Fig-
ure 7D). In SKOV3TR cells, R406 alone only slightly increased
the half-life of fluorescence recovery and did not have a signifi-
cant effect on mobile fractions. Thus, FRAP analysis confirmed
that SYK inactivation promoted paclitaxel-induced stabilization
of microtubules in paclitaxel-resistant cancer cells.
DISCUSSION
This study provides biological basis and pre-clinical evidence
that targeting SYK sensitizes tumor cells to paclitaxel, espe-
cially for those that have developed paclitaxel resistance. It is
likely that the paclitaxel-resistant cells with higher SYK levels
and activity have developed a molecular mechanism that
counteracts paclitaxel-mediated microtubule stabilization, thus
reducing paclitaxel-induced cytotoxicity. Our finding validates
a previous hypothesis that modulating microtubule stability can
enhance the cytotoxic response of ovarian cancer cells to pacli-
taxel (Ahmed et al., 2011). Indeed, by analyzing the SYK sub-
strates in paclitaxel-resistant ovarian cancer cells, we identified
tubulin and MAPs as substrates of SYK, raising the possibility
that SYK inactivation affects microtubule dynamics. The role of
SYK in cancer therapeutics has also been reported by others.
SYK activity has been demonstrated to play an important role
in imatinib or nilotinib resistance in CML (Gioia et al., 2011) and
the pentapeptide mimic targeting the substrate binding site
of SYK has an anti-tumor effect on chemotherapy-resistant
relapsed B-precursor leukemia cells (Uckun et al., 2010a).
How SYK tyrosine phosphorylation affects the functions of
tubulin and MAPs is not clear. Faruki et al. reported that tubulin,
upon SYK-mediated phosphorylation, was able to assemble into
microtubules (Faruki et al., 2000), but the effects on microtubuleCancer Cell 28, 82–96, July 13, 2015 ª2015 Elsevier Inc. 89
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dynamics remain to be determined. This is further complicated
by SYK-mediated phosphorylation on many microtubule inter-
acting proteins such as MAP1B and MAP4 that also play critical
roles in microtubule dynamics (Krisenko et al., 2014). MAP1B
and MAP4 bind to microtubules and facilitate their polymeriza-
tion and stabilization. Because serine phosphorylation of MAPs
has been shown to decrease interactions of MAPs and microtu-
bules, promoting microtubule dynamics (Chang et al., 2001;
Goold et al., 1999; Trivedi et al., 2005), it is likely that tyrosine
phosphorylation by SYK has a similar effect because SYK
phosphorylates MAP4 at tyrosine Y1001, which resides in the
conserved microtubule binding domain of MAP4.
The observation that R406 alone is sufficient to reduce cellular
proliferation at doses that do not significantly affect microtubule
stability suggests that the anti-proliferative activity of R406 can
also be attributed to inactivation of SYK-regulated tumor-pro-
moting pathways. By analyzing the SILAC data, we also identi-
fied several SYK substrates that belong to canonical tumor-pro-
moting pathways. These include STAT3, which has been
reported as a substrate for SYK in hematopoietic cells (Uckun
et al., 2010b). R406 markedly reduces phosphorylation of
STAT3 tyrosine residues Y704 and Y705, the latter of which is
associated with STAT3 activity and its anti-apoptotic effect
(Chen et al., 2008). In addition, we identified a group of SYK sub-
strates including PIK3R1/2 and adaptor proteins, GAB1/2 and
SHC, that are involved in the growth factor/PI3K signaling. These
proteins generally couple signaling among activated growth
factor receptors upon ligand binding such as VEGF, EGF,
IGF1, and HGF (Holgado-Madruga and Wong, 2003) with PI3K
signaling pathway, which has been known to participate in
chemoresistance (Koti et al., 2013). Thus, our data suggest
that the anti-tumor effects of inactivating SYK come from two
broad mechanisms—stabilizing microtubules and suppressing
growth-promoting signaling pathways. For the latter, we demon-
strated that R406 suppressed phosphorylation of other SYK
substrates including pSTAT3 and pAKT of which phosphoryla-
tion was reported to protect tumor cells from chemotherapy-
induced cytotoxicity. However, unlike the synergistic effect on
microtubule stability, adding paclitaxel did not further reduce
their phosphorylation levels (data not shown). Thus, we focus
on the biological effects of targeting SYK signaling on microtu-
bule dynamics.
Microtubules have been well established as a major target for
cancer treatment. The anti-mitotic microtubule-targeting drugs
include (1) vinca alkaloids (vinblastine, vincristine, vindesine,
and vinorelbine) that bind to a– and b-tubulin heterodimers, pre-
venting their incorporation into microtubules and microtubule
polymerization; and (2) microtubule-stabilizing agents such as
paclitaxel and docetaxel (collectively known as taxanes) that(D) In vitro kinase assay using recombinant active SYK and purified bovine mic
MAP1B and MAP4.
(E) Tyr-phosphorylated (pTyr) and total a-tubulin and MAP1B in naive and paclitax
and paclitaxel-resistant cells for each cell line were blotted on the same membran
comparison of the naive and paclitaxel-resistant conditions.
(F) Pearson correlation analysis between Tyr-phosphorylated MAP1B/MAP1B ra
(G) Correlation between the levels of total and phospho-SYK and phospho-tubu
(H) Representative images of SYK, phospho-SYK (Y525/526), and phospho-a
See also Figure S5 and Tables S2 and S3.directly interact with and stabilize microtubules (Liu et al.,
2014). Thus, SYK inhibitors represent another group of drugs
that affect microtubules through regulating phosphorylation of
tubulin andMAPs. The different mechanisms used by SYK inhib-
itors and paclitaxel may explain their synergistic effect in cancer
cells, especially in those that developed paclitaxel resistance.
Our results may have important clinical ramifications because
taxanes are frequently used in treating several major types of
cancer such as breast and lung carcinoma in addition to ovarian
carcinoma. Because development of taxane resistance is com-
mon, introduction of regimens to overcome paclitaxel resistance
is an unmet need.
The main SYK inhibitor used in this study is R406, the active
form of fostamatinib (also known as R788), which is orally admin-
istrable and highly tolerable when used in late-phase clinical
trials of rheumatoid arthritis, auto-immune diseases, and hema-
tologic malignancies (Friedberg et al., 2010; Podolanczuk et al.,
2009;Weinblatt et al., 2010). Several clinical trials of fostamatinib
have reported its pharmacokinetics and safety profile at a range
of doses up to 250 mg twice daily (Friedberg et al., 2010; Wein-
blatt et al., 2008). The plasma concentration reported from these
studies ranges between 300 and 1,800 ng/ml (molar concentra-
tion 0.5–2.9 mM), which is relevant to the R406 concentrations
used in our experiments. Therefore, the availability of fostamati-
nib and the minimal overlap between observed clinical toxicities
of fostamatinib and paclitaxel would facilitate the translation
of the current pre-clinical study (Weinblatt et al., 2010). For
example, results of our study warrant determining the benefit
of adding fostamatinib to the weekly paclitaxel regimen used in
treating recurrent ovarian cancer.
Finally, the current study focuses on demonstrating the direct
function of SYK on microtubule constituents and concludes that
the major mechanism for SYK inhibitors to sensitize paclitaxel ef-
fects is through altering the SYK-MAP-tubulin axis. Because SYK
may havemultiple roles in promoting tumor progression, it should
not be construed that other SYK-regulated microtubule-indepen-
dentpathwaysarenot involved inpaclitaxel resistance. In fact, this
study also validated that bothSTAT3andAKTwere the substrates
of SYKand their inhibition canenhance cytotoxicity of chemother-
apeutic agents, although the underlying mechanisms have yet to
be further elucidated (Lin et al., 2015; Abubaker et al., 2014).
EXPERIMENTAL PROCEDURES
Detailed materials and methods are provided in the Supplemental Experi-
mental Procedures.
Immunohistochemistry
Formalin-fixed and paraffin-embedded ovarian cancer tissues were obtained
from the Department of Pathology at the Johns Hopkins Hospital, Baltimore,rotubule-associated protein (MAP). Immunoprecipitation was used to enrich
el-resistant (TR) SKOV3 andMPSC1 cells. For the IP: MAP1B panels, the naive
e but not on the adjacent lane. The images were cropped to allow side-by-side
tio and sensitivity to paclitaxel in a group of ovarian cancer cell lines.
lin (Y272) using immunohistochemistry in 161 ovarian carcinomas.
tubulin (Y272) immunostaining. Scale bar represents approximately 400 mm.
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Table 1. Candidate of SYK Substrates Related to Microtubules
Gene
Symbol Full Name Accession Phosphopeptide
Protein
Phosphorylation Site
Exp. 1
H/L Ratio
Exp. 2
H/L Ratio
DCTN2 dynactin 2 (p50) NP_006391 TGYESGEyEMLGEGLGVK Y91 0.50 0.72
MAP1B microtubule-associated
protein 1B
NP_005900 AAEAGGAEEQyGFLTTPTK Y1062 0.37 0.59
SPPLIGSESAyESFLSADDKASGR Y1410 0.47 0.89
ESSPLySPTFSDSTSAVK Y1796 0.34 0.64
ESsPLySPTFSDSTSAVK Y1796, S1793 0.32 0.57
TSDVGGYYyEK Y1906 0.47 0.67
SPSDSGySYETIGK Y1921 0.41 0.70
SPSDSGYSyETIGK Y1923 0.37 0.70
TPEDGDySYEIIEK Y1938 0.47 0.41
TPEDGDYSyEIIEK Y1940 0.44 0.65
TPDTSTyCYETAEK Y2040 0.40 0.65
TPDTSTYCyETAEK Y2042 0.40 0.65
TATCHSSSSPPIDAASAEPyGFR Y1830 0.27 0.64
TPEEGGySYDISEK Y1955 0.40 0.50
TTKTPEDGDySYEIIEK Y1938 0.49 0.64
VLSPLRsPPLIGSESAyESFLSADDK Y1410, S1400 0.23 0.44
YESSLYSQEySKPADVTPLNGFSEGSK Y1174 0.36 0.48
MAP4 microtubule-associated
protein 4
NP_002366 KVSySHIQSK Y1001 0.34 0.74
TBCB tubulin folding co-factor B NP_001272 LGEyEDVSR Y98 0.52 0.94
TUBA4A tubulin a-4A NP_005991 IHFPLATyAPVISAEK Y272 0.30 0.48
TUBA3E tubulin a-3E NP_997195
TUBA3D tubulin a-3D NP_525125
TUBA3C tubulin a-3C NP_005992
TUBA1C tubulin a-1C NP_116093
TUBA1B tubulin a-1B NP_006073
TUBA1A tubulin a-1A NP_006000
TUBA8 tubulin a-8 NP_061816 QLFHPEQLITGKEDAANNyAR Y103 0.38 0.69
TUBA4A tubulin a-4A NP_005991
TUBA3D tubulin a-3D NP_525125
TUBA3C tubulin a-3C NP_005992
TUBA1C tubulin a-1C NP_116093
TUBA1B tubulin a-1B NP_006073
TUBA1A tubulin a-1A NP_006000
TUBA8 tubulin a-8 NP_061816 VGINyQPPTVVPGGDLAK Y357 0.34 0.43
TUBA4A tubulin a-4A NP_005991
TUBA3E tubulin a-3E NP_997195
TUBA3D tubulin a-3D NP_525125
TUBA3C tubulin a-3C NP_005992
TUBA1C tubulin a-1C NP_116093
TUBA1B tubulin a-1B NP_006073
TUBA1A tubulin a-1A NP_006000
TUBB tubulin b NP_821133 ISVYyNEATGGK Y51 0.45 0.57
TUBB tubulin b NP_821133 NSsYFVEWIPNNVK Y340 0.49 0.43
TUBB6 tubulin b-6 NP_115914
TUBB4A tubulin b-4A NP_006078
TUBB3 tubulin b-3 NP_006077
TUBB4B tubulin b-4B NP_006079
TUBB2B tubulin b-2B NP_821080
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Figure 6. Effects of Ectopic SYKExpression
on Paclitaxel Sensitivity and Tyrosine Phos-
phorylation of MAP1B and MAP4 in SKOV3
(A) Western blot analysis shows expression of
ectopic SYK-WT and SYK-130E with and without
induction.
(B) Paclitaxel IC50 in cells expressing ectopic SYK-
WT and SYK-130E as compared to non-induced
cells (+Tet). *p < 0.05; **p < 0.01 as determined by
one-way ANOVA with Tukey’s post hoc test.
(C) MAP1B and MAP4 tyrosine phosphorylation in
SYK-130E-expressing cells. Results are shown as
mean ± SEM. See also Figure S6.Maryland. All studies were Johns Hopkins University School of Medicine
Institutional Review Board exempt because no protected health information
was used. To compare the expression levels of SYK in paired recurrent
post-chemotherapy ovarian HGSC and their primary untreated tumors, we
performed immunohistochemistry. The primary tumors from HGSC patients
were optimally debulked to a residual tumor volume less than 1 cm, and all
patients received standard carboplatin and paclitaxel therapy for three to six
cycles. Paraffin tissues were arranged in tissue microarrays to facilitate immu-
nohistochemistry and to ensure that tissues were stained under the same con-
ditions. The 214 effusions were obtained from the Norwegian Radium Hospital
(177 peritoneal, 37 pleural) were from 211 patients (two patients had two effu-
sions) diagnosed with serous carcinoma in the years 1998–2005. One hundred
twenty-three effusions were collected at diagnosis prior to chemotherapy,
whereas 88 effusions were post-chemotherapy specimens, collected at dis-
ease recurrence. Data regarding previous chemotherapy were unavailable
for three patients. The FIGO stages were one patient with stage I, four with
stage II, 127 with stage III, and 82 with stage IV disease. Residual tumor vol-
ume was %1 cm in 86 cases, >1 cm in 95 cases, and unknown in 33 cases.
The majority of patients (n = 193) received platinum-based chemotherapy at
diagnosis. Chemotherapy response was classified as complete response,
117 patients; partial response, 31 patients; stable disease, 12 patients; and
progression, 28 patients. The disease response after chemotherapy for the re-
maining cases (n = 23) could not be evaluated because of adverse effects,
normal CA-125 after primary surgery or missing CA-125 information and no
grossly residual tumor. The study was approved by the Regional Committee
for Medical Research Ethics in Norway. Comparative analysis was performed
for patients with complete response versus partial response/stable disease/
progression. The statistical program used was SPSS version 18. The test for
association with chemotherapy response was Mann-Whitney.
The mouse monoclonal anti-SYK antibody [4D10.1] (Abcam ab3113), anti-
phospho-SYK (Tyr525/526) antibody (CST #2711), and anti-a-tubulin (phos-
pho Y272) antibody [EP1334(2)Y] (Abcam ab76290) were used, and their
specificity was confirmed by western blotting. The specificity of anti-phos-
pho-SYK (Y525/526) antibody in immunohistochemistry was previously vali-
dated using anti-BCR stimulated B-lymphoma cells and tissues (Cheng
et al., 2011). Citrate-based Target Retrieval Solution (DAKO) was used for an-
tigen retrieval (95C–100C for 20 min). The sections were then incubated withCancer Cell 28, 8the primary antibody at 4C overnight and the
appropriate secondary antibody at room tempera-
ture for 30 min. Colorimetric development was de-
tected by the EnVision+System (DAKO). Sections
were counterstained with hematoxylin, and immu-
noreactivity was scored using the H score system
by two investigators based on the percentage of
positively stained cells and the intensity of stain-
ing, which ranged from 0 to 3+. A composite score
was determined by multiplying the intensity and
extent scores.
Xenograft Mouse Tumor Models
Two models were used in this study. In the sub-
cutaneous tumor model, a tumorigenic line ofSKOV3 cells, SKOV3c.2 cells, were mixed with an equal volume of Matrigel
(BD Biosciences) and injected subcutaneously (5 3 106 cells/injection) into
female nu/nu mice. Tumor growth was monitored by measurements of tumor
diameters, and the tumor volume was calculated. Treatment with drugs
started as soon as the tumor became palpable. At the end of treatment,
all tumors were excised, weighed, and confirmed by histology. For BrdU
incorporation, mice were intraperitoneally injected with 150 mg/kg and killed
2 hr post-injection. Tumor cells that had incorporated BrdU were detected in
paraffin-embedded sections with an anti-BrdU antibody. The number of total
tumor cells and positively stained tumor cells were counted.
In the intraperitoneal tumor model, SKOV3 luciferase expressing cells (5 3
106) were injected intraperitoneally into female nu/nu nude mice. Paclitaxel
treatmentwas initiatedwhen luminescence signal reached>23 106 photons/s.
Mice were treated with vehicle (control) or paclitaxel intraperitoneally three
times per week for up to 7 weeks. Tumor burden was measured weekly in
mice injected with d-luciferin using the IVIS Spectrum In Vivo Imager. IC50 of
paclitaxel was determined in primary cultures established from individual tu-
mors. Paclitaxel-resistant cellswere expandedand re-injected intraperitoneally
into a new cohort of mice to examine the anti-tumor activity of single-agent
R406, paclitaxel, or the combination. When tumor luminescence signals ex-
ceeded 2 3 106 photons/s, mice received intraperitoneal administration of
vehiclecontrol,R406 (10mg/kg), paclitaxel (10mg/kg), or thecombination three
times per week. All of the animal procedures were approved by the Johns Hop-
kins University Animal Care Committee.
Fluorescence Recovery after Photobleaching
SKOV3 and SKOV3TR cells were transfected with a plasmid expressing
GFP-a-tubulin, andmultiple positive clones were pooled for further expansion.
Photobleaching procedures were performed using a confocal laser-scanning
microscope. The dynamics parameters recorded from FRAP included the frac-
tion of microtubules that recovered within 2 min after photobleaching (mobility
fraction), and the time it took for half of the mobile fraction of microtubules to
recover (t1/2). Regions of interest were bleached for 10 s followed by 2 min of
observation, with image acquisition every 2 s. At least 12–15 observations
were recorded per sample, and the recovered fluorescence intensities were
normalized against background and unbleached regions within the cell of
interest (Daniels et al., 2009).2–96, July 13, 2015 ª2015 Elsevier Inc. 93
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Figure 7. Combination of SYK Inhibitor and Paclitaxel Results in Microtubule Stabilization in Paclitaxel-Resistant Ovarian Cancer Cells
(A) Immunoblottings of acetyl or detyrosinated tubulin after treatment with DMSO, R406 (2.5 mM), paclitaxel (30 nM), or a combination of R406 (2.5 mM) and
paclitaxel (30 nM) in indicated cell lines.
(B) Immunoblotting analysis of acetyl-a-tubulin in tumor xenografts (two representative tumors from each group) comparing combination of R406 and paclitaxel
to vehicle or single agents. Statistical significance is determined by one-way ANOVA with Tukey’s post hoc test. ***p < 0.001.
(C and D) FRAP assay analysis of mobility fraction between the group treated with paclitaxel and the group co-treated with R406 and paclitaxel in SKOV3 cells
(C) and SKOV3TR cells (D). Mobility fraction and T1/2 were analyzed by one-way ANOVAwith Tukey’s post hoc test. *p < 0.05; **p < 0.01; ***p < 0.001. Results are
shown as ± SEM. See also Figure S7.
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